P70S6K is a mitogen-activated Ser/Thr protein kinase that is required for cell growth and G1 cell cycle progression. This kinase is controlled by multiple phosphorylation events located within the catalytic, linker and pseudosubstrate domains and subsequently phosphorylates specifically ribosomal protein S6.
What is S6K1 phosphorylation?
Ribosomal protein S6 kinase beta-1 (S6K1), also known as p70S6 kinase (p70S6K, p70-S6K), is an enzyme (specifically, a protein kinase) that in humans is encoded by the RPS6KB1 gene. Phosphorylation of S6 induces protein synthesis at the ribosome.
What activates S6K?
In the classical insulin signaling pathway, S6K is activated by mTOR at the downstream of PI3K/Akt. The activation involves in S6K phosphorylation at T389 by mTOR, which enhances protein synthesis through phosphorylation of ribosomal protein S6 by S6K.
What is S6K in biology?
S6K is a serine/threonine kinase that is a member of the ribosomal S6 kinase (RSK) family. S6K exists in two main isoforms, S6K1 and S6K2, which can also be alternatively spliced to produce different splice forms.
What does mTOR pathway regulate?
The mTOR pathway is a central regulator of mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue, and the brain, and is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers.
What do ribosomal proteins do?
Ribosomal proteins are proteins that constitute ribosomes. Ribosomal proteins may be structurally important within the ribosome, for instance in interacting with the RNA component (rRNA), and may also function directly in translating mRNA into protein, which is the main function of ribosomes.
What are mTOR inhibitors used for?
Mammalian target of rapamycin (mTOR) inhibitors are used in treatment of renal cancer and is being studied for use in other types of cancers. More benefits are being seen when MTOR inhibitors are combined with other chemotherapy agents.
